AFT PHARMACEUTICALS LIMITED — Earnings Release 2020

May 19, 2020

==> picture [174 x 30] intentionally omitted <==

Results for announcement to the market	Results for announcement to the market	Results for announcement to the market	Results for announcement to the market
AFT Pharmaceuticals Limited
Reporting Period	12 months to 31 March 2020
Previous Reporting Period	12 months to 31 March 2019
Currency	NZ$
	Amount (000s)	Percentage change
Revenue from continuing operations	$105,597	Up 24%
Total Revenue	$105,597	Up 24%
Net profit/(loss) from continuing operations	$12,692	Up 623%
Total net profit/(loss)	$12,692	Up 623%
Interim/Final Dividend
Quoted Equity Securities:
Amount per Quoted Equity Security	No dividends have been paid on ordinary shares and it is currently not proposed to pay dividends.
Imputed amount per Quoted Equity Security	Not Applicable
Record Date	Not Applicable
Dividend Payment Date	Not Applicable
Unquoted Equity Securities:
Amount per Unquoted Redeemable Preference Share	3.2c for each payment
Imputed Amount per Unquoted Redeemable Preference Share	3.2c for each payment
Record Dates	14 September 2019, 14 December 2019, and 14 March 2020
Dividend Payment Dates	30 September 2019, 31 December 2019, and 31 March 2020
	Current period		Prior comparable period
Net tangible assets per Quoted Equity Security	($0.10)		($0.03)
A brief explanation of any of the figures above necessary to enable the figures to be understood	Accompanying this announcement are the Group’s audited consolidated financial statements for the twelve months ended 31 March 2020. These financial statements and the full year results commentary dated 20 May 2020 provide the balance of information requirements in accordance with NZX Listing Rule 3.5 and Appendix 2. Pursuant to ASX listing rule 1.15.3 AFT Pharmaceuticals Limited confirms that it continues to comply with the rules of its home exchange (NZX Main Board).

	The unquoted Redeemable Preference Shares issued on 24 March 2017 attract a dividend rate of 9.4% per annum, or 25.8 cents per share per annum. For the 30 September 2019, 31 December 2019 and 31 March 2020 quarter ends, 50% of the dividend was paid in cash and included in the above table. For the 30 June 2019 quarter end no cash dividends were paid. The remaining 50% of dividends net of withholding taxes for the 30 September 2019, 31 December 2019 and 31 March 2020 quarter ends together with 100% of the dividends net of withholding taxes for the 30 June 2019 quarter end have been accumulated in the Redeemable Preference Share Reserve.
Authority for this announcement
Name of person authorised to make this announcement	Malcolm Tubby
Contact person for this announcement	Malcolm Tubby, Chief Financial Officer, AFT Pharmaceuticals Ltd
Contact phone number	+64 9 488 0232
Contact email address	malcolm@aftpharm.com
Date of release through MAP	20 May 2020

Audited financial statements accompany this announcement.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969